The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced two key appointments to its management team.
Richard White has joined the Company as Business Development Manager, and Pardeep Sharda as Senior Product Manager. The appointments follow the Native Antigen Company’s recent move to new state-of-the-art facilities at the Oxford Technology Park and form part of its strategy to further expand its extensive product portfolio, with over 30 new products in the pipeline.
These appointments mark a major milestone for us as we continue to grow the Company both in terms of size and of our product offerings. Coupled with the news of our brand new, cutting-edge facilities opening in Oxford, the expansion of our senior team makes for a very exciting time for The Native Antigen Company.
Ish Jalal, Commercial Director, The Native Antigen Company
Richard will be responsible for growing the Company’s presence in the North American market and ensuring both customers and the business are supported as the Company continues to expand. Richard brings with him over 20 years’ diverse commercial experience in multiple functions including sales, marketing, and diagnostics.
His expertise includes developing and executing tactical business strategies to enhance efficiency and branding for diagnostics. As Senior Product Manager, Pardeep will focus on building and developing marketing strategies both for the Company’s existing product range and assisting in the design of innovative new products. Pardeep has extensive experience in driving marketing strategies, with his most recent roles including Senior Global Product Manager at QIAGEN, and Marketing Manager at Roche.
I’m looking forward to working with the team at The Native Antigen Company, continuing on the growth trajectory that the Company has already seen over the past few years. With the Company’s recent move to new facilities, we have greatly increased our capacity, giving exciting opportunities for new business, as well as enabling us to continue to anticipate and support our existing customers needs.
Richard White, Business Development Manager, The Native Antigen Company
Strengthening the Native Antigen Company’s management team will facilitate its drive to scale-up manufacturing of infectious disease reagents, antibodies and assays as part of the Company’s transition to the brand-new facility, opened by LGC Clinical Diagnostics at the Oxford Technology Park. The 36,000 square foot facility was officially opened in October by the creators of the Oxford AstraZeneca COVID-19 vaccine, Dame Sarah Gilbert DBE and Teresa Lambe OBE, and will host the manufacturing facilities for The Native Antigen Company alongside an advanced workflow applications laboratory for LGC Biosearch Technologies.
This is a fantastic time to be joining the team, as we enter the next stage of the Company’s development. With LGC’s backing, there is huge scope for further product development and expansion of our core capabilities, which I am looking forward to being a part of.
Pardeep Sharda, Senior Product Manager, The Native Antigen Company
The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant